Search the Newsreel

All 9 Evaluable Patients Responded in Alpha Tau Cancer Trial

Alpha Tau (Nasdaq: DRTS) announced positive clinical trial results for its Alpha DaRT® therapy combined with pembrolizumab in elderly patients with advanced head and neck cancer, achieving a 100% objective response rate among all 9 evaluable patients. The study reported a median overall survival …

100% cancer response in Alpha DaRT trial for Alpha Tau Medical (Nasdaq: DRTS)

Alpha Tau Medical Ltd. reported positive clinical data for its Alpha DaRT® therapy combined with pembrolizumab in elderly head and neck cancer patients, achieving a 100% objective response rate in nine evaluable patients. The study showed favorable median overall survival of 18.2 months and …

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Alpha Tau Medical Ltd. announced the successful treatment of the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma (cSCC) in its ADMIRE study. The treatment, using Alpha DaRT, was performed at Banner MD Anderson Cancer Center. This study specifically targets immunocompromised patients who …

Alpha Tau Medical (DRTS) Reaches ADMIRE Milestone, Is The Stock Now Fully Valued?

Alpha Tau Medical (DRTS) recently reported a significant milestone in its ADMIRE clinical study, successfully treating an immunocompromised patient with recurrent cutaneous squamous cell carcinoma using Alpha DaRT. This news has coincided with a substantial increase in its share price. Despite this clinical success …

Barclays Sticks to Its Buy Rating for Alpha Tau Medical Ltd (DRTS)

Barclays analyst Lukas Shumway reiterated a Buy rating for Alpha Tau Medical Ltd (DRTS) with a $17.00 price target. The company reported a GAAP net loss of $22.94 million in its latest quarter, and corporate insider sentiment is negative, with recent share sales.

Alpha Tau Medical (DRTS) Is Up 6.6% After First Immunocompromised cSCC Patient Treated With Alpha DaRT

Alpha Tau Medical's stock rose 6.6% after successfully treating the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma (cSCC) using its Alpha DaRT therapy in the ADMIRE trial. This development expands the potential market for the Alpha DaRT platform by addressing a high-need …

H.C. Wainwright reiterates Alpha Tau Medical stock rating on immunocompromised patient treatment

H.C. Wainwright has reiterated a Buy rating and a $15.00 price target for Alpha Tau Medical (NASDAQ:DRTS) after the successful treatment of the first immunocompromised patient with recurrent cutaneous squamous cell carcinoma in the ADMIRE study. This treatment utilized Alpha DaRT, a localized therapy …

Alpha Tau Medical (NASDAQ:DRTS) Stock Price Up 7.1% - Should You Buy?

DRTS Q1 2026 Earnings: EPS Miss Reflects Higher R&D Costs as Alpha DaRT Clinical Progress Continues

DRTS Forecast — Price Target — Prediction for 2027

Alpha Tau Medical earnings missed by $0.14, revenue fell short of estimates

DRTS Stock Rises Overnight: Early US Brain Cancer Trial Results Expected Today

Alpha Tau Medical: 2026 Is The Breakthrough Year